Gilbert Amelio Net Worth
The estimated Net Worth of Gilbert F Amelio is at least $1.05 Million dollars as of 5 September 2019. Gilbert Amelio owns over 30,000 units of Galectin Therapeutics stock worth over $498,456 and over the last 9 years he sold GALT stock worth over $552,420. In addition, he makes $0 as Independent Director at Galectin Therapeutics.
Gilbert Amelio GALT stock SEC Form 4 insider trading
Gilbert has made over 9 trades of the Galectin Therapeutics stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of GALT stock worth $99,000 on 5 September 2019.
The largest trade he’s ever made was exercising 103,750 units of Galectin Therapeutics stock on 21 January 2019 worth over $185,713. On average, Gilbert trades about 4,361 units every 66 days since 2011. As of 5 September 2019 he still owns at least 124,614 units of Galectin Therapeutics stock.
You can see the complete history of Gilbert Amelio stock trades at the bottom of the page.
Gilbert Amelio biography
Dr. Gilbert F. Amelio is an Independent Director of the Company. He a director since February 2009, began his career at Bell Labs in Murray Hill, New Jersey. Since January 1, 2012, Dr. Amelio has provided consulting and advisory services through GFA, LLC, a California limited liability company. He was a Senior Partner of Sienna Ventures (a privately-held venture capital firm in Sausalito, California) from April 2001 until the fund closed per plan on December 31, 2011. Dr. Amelio was Chairman and Chief Executive Officer of Jazz Technologies, Inc. (now a wholly owned subsidiary of Tower Semiconductor Ltd., an independent specialty wafer foundry) from August 2005 until his retirement in September 2008 (when he was named Chairman Emeritus). Dr. Amelio was Chairman and Chief Executive Officer of Beneventure Capital, LLC (a full-service venture capital firm in San Francisco, California) from 1999 to 2005 and was Principal of Aircraft Ventures, LLC (a consulting firm in Newport Beach, California) from April 1997 to December 2004. Dr. Amelio was elected a Director of AT&T in February 2001 and had previously served as an Advisory Director of AT&T (then known as SBC Communications Inc.) from April 1997 to February 2001. He served as a Director of Pacific Telesis Group from 1995 until the company was acquired by AT&T in 1997. Prior to 1997, he served as Chairman, President and CEO of National Semiconductor (1991-1996) and Apple Computer (1996-1997).
How old is Gilbert Amelio?
Gilbert Amelio is 75, he’s been the Independent Director of Galectin Therapeutics since 2009. There are 1 older and 12 younger executives at Galectin Therapeutics. The oldest executive at Galectin Therapeutics, Inc. is Gilbert Omenn, 77, who is the Independent Director.
What’s Gilbert Amelio’s mailing address?
Gilbert’s mailing address filed with the SEC is 208 S. AKARD STREET, , DALLAS, TX, 75202.
Insider trading at Galectin Therapeutics
Over the last 9 years, insiders at Galectin Therapeutics have traded over $21,025,907 worth of Galectin Therapeutics stock and bought 4,966,809 units worth $21,121,556 . The most active insider traders include Richard E Uihlein, James C Czirr, and Fund, L.P.10 X Capital Mana…. On average, Galectin Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $372,062. The most recent stock trade was executed by Kevin D Freeman on 6 September 2019, trading 1,290 units of GALT stock currently worth $4,786.
What does Galectin Therapeutics do?
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
What does Galectin Therapeutics’s logo look like?
Complete history of Gilbert Amelio stock trades at Galectin Therapeutics, InterDigital, AT&T, and AT&T
Galectin Therapeutics executives and stock owners
Galectin Therapeutics executives and other stock owners filed with the SEC include:
- Harold Shlevin, President, Chief Executive Officer, Chief Operating Officer
- Jack Callicutt, Chief Financial Officer, Secretary
- James Czirr, Independent Director
- Marc Rubin, Independent Director
- Eliezer Zomer, Executive Vice President – Manufacturing and Product Development
- Stephen Shulman, Independent Director
- Gilbert Omenn, Independent Director
- Joel Lewis, Independent Director
- Kevin Freeman, Independent Director
- Kary Eldred, Independent Director
- Gilbert Amelio, Independent Director
- Richard Uihlein, Director
- J. Rex Horton, Executive Director – Regulatory Affairs and Quality Assurance
- Adam Allgood, Executive Director of Clinical Development
- Theodore Daniel Zucconi, Director
- John F Mauldin, Director
- Fund, L.P.10 X Capital Mana…,
- Steven Prelack, Director
- Arthur Greenberg, Director
- Fund, L.P.10 X Capital Mana…,
- Peter G Traber, CEO and President
- Herman Paul Pressler, Director
- Thomas Mcgauley, Chief Financial Officer
- Rod D Martin, Director
- Jerald K Rome, Director